Register for your FREE account now and join the thousands of healthcare professionals who have depended on us for over 26 years for accurate, concise, and timely drug information.

Keep me logged in Forgot your password?

Please wait...

Please wait...

NORDITROPIN FLEXPRO PEN

Compare NORDITROPIN FLEXPRO PEN  to:
Compare
Compare

Generic Name for NORDITROPIN FLEXPRO PEN

Somatropin (rDNA origin) 5mg, 10mg, 15mg; per 1.5mL prefilled pen; soln for SC inj.

Legal Classification:

Rx

Pharmacological Class for NORDITROPIN FLEXPRO PEN

Growth hormone (GH).

Manufacturer of NORDITROPIN FLEXPRO PEN

Novo Nordisk

Indications for NORDITROPIN FLEXPRO PEN

Growth failure in children due to inadequate endogenous GH secretion. Children with short stature associated with Noonan or Turner syndrome. Children with short stature born small for gestational age (SGA) with no catch-up growth by age 2–4yrs. Adults with childhood-onset or adult-onset GH deficiency.

Adult dose for NORDITROPIN FLEXPRO PEN

Inject SC; rotate sites. Weight-based: Initially up to max 0.004mg/kg per day; may increase after 6 weeks to max 0.016mg/kg per day. Non-weight based: approx. 0.2mg/day (range: 0.15–0.3mg/day), may increase gradually every 1–2 months by increments of approx. 0.1–0.2mg/day.

Children's dosing for NORDITROPIN FLEXPRO PEN

Inject SC; rotate sites. Individualize. GH deficient: 0.024–0.034mg/kg per day, 6–7 times/week. Short stature w. Noonan: up to 0.066mg/kg per day. Short stature w. Turner or SGA: up to 0.067mg/kg per day.

Also:

Contraindications for NORDITROPIN FLEXPRO PEN

Acute critical illness. Acute respiratory failure. Closed epiphyses. Active malignancy or growing intracranial tumors. Diabetic retinopathy. Prader-Willi syndrome (severely obese or w. respiratory impairment); see literature.

Warnings/Precautions for NORDITROPIN FLEXPRO PEN

Monitor gait, thyroid function, glucose tolerance, for malignant transformation of skin lesions, and for intracranial hypertension (do baseline and periodic funduscopic exams). History of intracranial lesions: monitor for lesion progression or recurrence. Prader-Willi syndrome: evaluate baseline respiratory function; monitor weight and for respiratory infection. Discontinue if signs of upper airway obstruction or sleep apnea occurs. Diabetes. Hypothyroidism. Scoliosis. Turner syndrome: evaluate for ear disorders (eg, otitis media); monitor for cardiovascular disorders (eg, stroke, aortic aneurysm/dissection, hypertension). Pregnancy (Cat.C). Nursing mothers.

Interactions for NORDITROPIN FLEXPRO PEN

Antagonized by glucocorticoids. Antidiabetic medications may need to be adjusted. May affect CYP3A4 substrates. Women on oral estrogen: may need higher somatropin dose.

Adverse Reactions for NORDITROPIN FLEXPRO PEN

Headache, inj site reactions, localized muscle pain, weakness, hypothyroidism, mild hyperglycemia, glucosuria, arthralgia, myalgia, fluid retention, edema, elevated serum phosphate, antibody formation, pancreatitis; also children: slipped capital femoral epiphysis. Long-term overdose may cause gigantism and/or acromegaly.

How is NORDITROPIN FLEXPRO PEN supplied?

Cartridges 5mg, 15mg—1 (use w. NordiPen device)
FlexPro prefilled pen—1
NordiFlex prefilled pen—1

Related Disease:

Growth Hormone Deficiency {GHD}
Pituitary disorders

Related Resources

Lupron Depot-PED Labeling Updated to Include 18 Year Data

October 28, 2011

Abbott announced that the FDA has approved a supplemental New Drug Application (NDA) for Lupron Depot-PED (leuprolide acetate for depot suspension) 1-month formulation.

Phase 3 Study of SR Human Growth Hormone for Growth Hormone Deficiency

September 27, 2011

Biopartners GmbH and LG Life Sciences (LGLS) Ltd. announced positive results from their Phase 3 study of LB03002, a once-a-week, sustained-release (SR) recombinant human growth hormone (hGH) for the treatment in children with growth hormone deficiency (GHD).

Phase 3 Study of AEZS-130 as Diagnostic Test for Adult Growth Hormone Deficiency

August 30, 2011

Aeterna Zentaris announced favorable results of its Phase 3 study with AEZS-130 as the first oral diagnostic test for adult growth hormone deficiency (AGHD).

Two Dosage Strengths of Lupron Depot-PED 3-Month Approved for Central Precocious Puberty

August 17, 2011

Abbott announced that the FDA has approved Lupron Depot-PED (leuprolide acetate for depot suspension) 11.25mg and 30mg for three-month administration for the treatment of children with central precocious puberty (CPP).

Extended Dosing Interval for Somatuline Depot Injection Approved

March 09, 2011

The FDA has approved revised labeling to include an extended dosing interval of Somatuline Depot (lanreotide; Ipsen) Injection for the treatment of acromegaly.

DDAVP NASAL SPRAY

Endocrine System > Pituitary disorders

Desmopressin acetate 10mcg/spray; nasal spray; contains benzalkonium chloride.

Updated: 11/26/2009

EGRIFTA

Endocrine System > Pituitary disorders

Tesamorelin 1mg/vial; pwd for SC inj after reconstitution; preservative-free.

GENOTROPIN

Endocrine System > Pituitary disorders

Somatropin (rDNA origin) lyophilized pwd 1.5mg (1.3mg/mL after reconstitution, preservative-free), 5.8mg (5mg/mL after reconstitution, preserved with m-Cresol), 13.8mg (12mg/mL after reconstitution, preserved with m-Cresol); for SC inj.

LUPRON DEPOT-PED

Endocrine System > Pituitary disorders

Leuprolide acetate 7.5mg, 11.25mg or 15mg; per kit; depot susp for IM inj; preservative-free.

LUPRON DEPOT-PED 3 MONTH

Endocrine System > Pituitary disorders

Leuprolide acetate 11.25mg, 30mg; per kit; depot susp for IM inj; preservative-free.

ASTELIN

Respiratory Tract > Rhinitis/rhinorrhea (intranasal products)

Adverse reactions updated.

Updated: 5/8/2012

 

ATRAPRO ANTIPRURITIC HYDROGEL

Dermatological Disorders > Pruritus and dry skin

Monograph added.

Updated: 4/25/2012

 

ATRAPRO DERMAL SPRAY

Dermatological Disorders > Pressure/neuropathic ulcers

Monograph added.

Updated: 4/24/2012

 

B-NEXA

Nutrition > Vitamins/minerals/supplements

Monograph added.

Updated: 4/30/2012

 

CETAPHIL DERMACONTROL OIL CONTROL FOAM WASH

Dermatological Disorders > Cleansers

Monograph added.

Updated: 5/10/2012

 

Endocrine System > Pituitary disorders

DOPAMINE AGONISTS (eg, bromocriptine, cabergoline): Bromocriptine and cabergoline are ergot derivative dopamine agonists that stimulate dopamine D2 receptors to inhibit ...
more »

Potentially Inappropriate Drugs for the Elderly (Beers List)

May 21, 2012

A list of drugs that may potentially be inappropriate for use in elderly patients due to their side effects. A description of the possible side effects is indicated next to each drug.

Osteoporosis Treatments

May 16, 2012

Osteoporosis treatment chart.

Mood Disorder Treatments

May 16, 2012

Mood disorder treatments for bipolar disorder, major depressive disorder, treatment resistant depression, premenstrual dysphoric disorder, and others.

Antiretroviral Contraindications and Drug Interactions Chart

May 16, 2012

HIV medication contraindications and drug interactions comparison chart.

Antiretroviral Treatment Chart

May 16, 2012

Antiretroviral dosing regimen chart for HIV.

ClinicalJobAdvisor

Loading...

More Jobs

© 2012 Haymarket Media, Inc.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions